Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Tuberculosis and HIV news

Show

From To
Increased expenditure on social security has benefits for TB control in the EU

Increased expenditure on social protection programmes – sickness, disability and unemployment benefits, old age pensions, housing support – is associated with improved tuberculosis (TB) control, according to an

Published
22 hours ago
By
Michael Carter
Call to action to halt the looming TB-diabetes co-epidemic

It is time to act and no time to waste. That is the urgent message of the report "The Looming Co-epidemic of TB-Diabetes: A Call to Action" launched jointly by the International Union Against Tuberculosis and Lung Disease (The Union) and the World Diabetes Foundation (WDF) at the opening day of the 45th Union World Conference on Lung Health in Barcelona. The report warns against the brewing storm of diabetes and tuberculosis (TB) that is no longer confined to the teacup.

Published
29 October 2014
From
Citizen News Service
WHO launches new guidelines on management of latent TB infection

For the first time, the World Health Organization (WHO) has issued guidelines on testing, treating and managing latent TB infection (LTBI) in individuals with high risk of developing the disease. These guidelines were launched today at the Global TB Symposium just before the start of the 45th Union World Conference on Lung Health in Barcelona.

Published
29 October 2014
From
Citizen News Service
Health Experts: Perfect Storm of Diabetes and Tuberculosis Must Be Headed Off

The report, The Looming Co-epidemic of TB Diabetes: A Call to Action (1), launched on the opening day of the 45th Union World Conference on Lung Health currently taking place in Barcelona, Spain October 28 - November 1, synthesizes evidence from the medical and scientific literature, promotes an international policy framework for action, and lays out a new research agenda to fill knowledge gaps. The report challenges the conventional approach to health policymaking, which has historically addressed infectious diseases and noncommunicable (or “chronic”) diseases independently.

Published
29 October 2014
From
International Union Against Tuberculosis and Lung Disease
WHO interim guidance on the use of delamanid in the treatment of MDR-TB

A new TB drug with a novel mechanism of action – delamanid - is now available for treatment of adults with multidrug-resistant tuberculosis (MDR-TB). Delamanid was granted conditional approval by the European Medicine Agency in April 2014. Information about this new drug however remains limited, since it has only been through Phase IIb trial and studies for safety and efficacy. WHO is therefore issuing “interim policy guidance” that lists five conditions that must be in place if delamanid is used to treat adults with MDR-TB

Published
29 October 2014
From
World Health Organization
Success short treatment against drug-resistant tuberculosis confirmed

In what has become known as the Bangladesh regimen, ITM’s Armand Van Deun and colleagues developed a treatment of only 9 months. This regimen replaces the currently recommended treatment of 18 to 24 months. In 2010, the researchers reported that this treatment increased the success rate from 65% to 88% for MDR-TB patients in Bangladesh. The treatment is based on a combination of existing drugs.The researchers report a favourable outcome in roughly 85% of cases, in spite of increasing levels of serious second-line drug resistance. A smaller study in Niger confirmed the outstanding results of the shorter treatment.

Published
28 October 2014
From
Institute of Tropical Medicine
UNITAID’s EXPAND-TB and TBXpert MTB-RIF Projects Detect Over A Quarter of all MDR-TB Cases

UNITAID welcomes new data in the World Health Organization’s new global report on tuberculosis (TB) which shows a 30% increase in case detection of multi-drug resistant TB (MDR-TB) in 2013, much of which is attributed to the roll out of the UNITAID-funded EXPAND-TB and TBXpert projects. UNITAID’s EXPAND-TB project enabled the installation of sophisticated testing platform technology in TB reference laboratories across 27 countries, bearing 40% of the MDR-TB burden. This provided the capability to detect MDR-TB for the first time for many countries.

Published
27 October 2014
From
UNITAID
TB Alliance Launches Phase 2B Clinical Trial of a Novel TB Drug Regimen that Could Cut Treatment Time by Half or More for a Majority of TB Patients

NC-005 trial tests a novel regimen of bedaquiline (Sirturo), pretomanid (formerly known as PA-824), and pyrazinamide; results could pave the way for a three-month TB treatment.

Published
27 October 2014
From
TB Alliance
WHO report shows progress on HIV-associated TB but pace needs to be faster

The Global Tuberculosis Report 2014 highlights that while the number of TB deaths among people living with HIV has been falling for almost a decade—from 540 000 in 2004 to 360 000 in 2013—early case detection, antiretroviral treatment, preventive therapy and other key activities need to be further scaled-up.

Published
27 October 2014
From
UNAIDS
Bedaquiline as part of tailored therapy for MDR- and XDR-TB achieves impressive culture conversion rates

Use of the new anti-tuberculosis (TB) drug bedaquiline as part of a tailored regimen achieved high rates of culture conversion in people with multidrug-resistant TB (MDR-TB) and extensively

Published
27 October 2014
By
Michael Carter
← First12345...86Next →

Filter by country